December 26, 2022 — AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced that the International Trade Commission (ITC) has issued its Final Determination ruling that Apple Watch infringed AliveCor’s patented technology. The ITC issued a Limited Exclusion Order (LEO), a cease and desist order and set a bond in the amount of $2.00 per unit of infringing Apple Watches imported or sold during the Presidential review period, potentially impacting sales of millions of infringing Apple Watches.
The ITC has suspended enforcement of its orders pending resolution of AliveCor’s appeal of the U.S. Patent and Trademark Office, Patent Trial and Appeal Board’s (“PTAB”) decision finding the asserted patents unpatentable. Today’s ruling marks a victory for AliveCor and affirms the Initial Determination issued in June by Administrative Law Judge (ALJ) Cameron Elliot of the ITC. The Final Determination will now undergo a 60-day review by President Biden.
In addition to fighting Apple on patent infringement in the ITC, AliveCor continues to seek relief in the Northern District of California from Apple’s anticompetitive behavior. That case is expected to go to trial in early 2024.
“Today's ITC ruling is a win for innovation and consumer choice,” said Priya Abani, CEO of AliveCor. “The ruling underscores the importance of upholding intellectual property rights for companies like AliveCor and scores of others whose innovations are at risk of being suppressed by a Goliath like Apple. We look forward to continuing to build and innovate on our cardiac solutions to improve people's lives.”
AliveCor has introduced a series of game-changing innovations in AI-powered cardiac care, including the first-ever FDA-cleared wireless, patchless, six-lead ECG sensor, the first and only personal ECGs to detect six of the most common arrhythmias, and the first FDA-cleared credit-card-sized personal ECG. With more than 170 patents issued and pending worldwide, AliveCor continues to protect its strong portfolio of innovations in accordance with established patent law.
For more information: www.alivecor.com
Related Wearable ECG Monitoring Content:
How Advances in Wearable Cardiac Monitors Improve the Patient and Clinician Experience
Cardea Solo Wearable ECG Collects High-altitude Cardiac Data on Denali Expedition
Cardiac Insight Partners With VivoSense for Cardiovascular Research
Wearable Cardiac Monitors Are Effective for Tracking Atrial Fibrillation Following Ablation
As Interpretation Criteria Evolve, False Positive Athlete ECG Screening Rates Can Decrease
March 06, 2026 
